Marianne Kirkegaard appointed new Chairman of Fertin Pharma’s Board of Directors

Marianne Kirkegaard appointed new Chairman of Fertin Pharma’s Board of Directors

Vejle, Denmark, 2 September 2019 – The shareholders of Fertin Pharma A/S (“Fertin Pharma”) have appointed Marianne Kirkegaard as new Chairman. She will replace Dr. Thomas Werner as of 1 September 2019. The shareholders would like to take the opportunity to thank Dr. Thomas Werner for his valuable contributions as Chairman.

New Chairman brings extensive global leadership experience
Marianne Kirkegaard brings more than 25 years of operational skills. She currently is President and CEO of CSM Bakery Solutions, which is a leading global company with over 7,000 employees and USD 2.5 billion in turnover. Marianne has extensive international experience and has worked closely with many of the world’s largest retailers from a business-to-business perspective. Prior to her current position, she has held leadership and board positions at companies such as Unilever, Carlsberg/Coca-Cola, Salling Group and AAK.

Rikke Kjær Nielsen, Partner at EQT Partners, comments:  ”We are happy to announce Marianne Kirkegaard as the new Chairman of Fertin Pharma. Marianne has experience from the entire value chain in companies with significant international operations. She has been deeply involved in R&D and category management – always with an end-consumer perspective, skills we believe will be highly beneficial to Fertin Pharma as the company continues its transformation and development.”

Strategy to become a world leader in innovative oral drug delivery formats
Headquartered in Vejle, Denmark, Fertin Pharma’s strategy is to become a world leader in innovative oral delivery formats for the pharmaceutical and nutraceutical industry. The company has more than 40 years of experience and unique capabilities in oral delivery of active ingredients. Today, Fertin Pharma has 75 employees in its research and development team. The company’s blue-chip customers are served through a wide portfolio of proprietary technologies including chewing gum, lozenges, pouch powder as well as the innovative ZapLiq® platform. New formats are continuously developed in partnership with customers.

Marianne Kirkegaard, newly appointed Chairman of Fertin Pharma, comments: “I am impressed with the depth of the competences and strive for innovation that exists in Fertin Pharma’s organisation. The company has gone through a period of rapid change as it has expanded its customer, technology and manufacturing footprint. I look forward to supporting the continued growth journey of Fertin Pharma.”

For further information, please visit or contact:
Rikke Kjær Nielsen, Partner EQT Partners,
Marianne Kirkegaard, Chairman Fertin Pharma,
Søren Birn, CEO Fertin Pharma,

Subscribe to Newsletters

And stay informed about our news and events